Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

The company's lineup also includes other blockbuster drugs with strong momentum. Sales of autoimmune disease drug Taltz, breast cancer drug Verzenio, and fast-acting insulin Humalog soared by 17% or ...

Insulet Co. (NASDAQ:PODD – Get Free Report)’s stock price reached a new 52-week high during trading on Thursday after JPMorgan Chase & Co. raised their price target on the stock from $280.00 to ...

Tandem Diabetes Care, Inc. TNDM announced that the in-warranty users of the t:slim X2 insulin pump in Canada can now access full compatibility with both Dexcom’s DXCM G7 and G6 Continuous Glucose ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

purchased a new position in shares of Insulet in the 3rd quarter valued at $297,000 ... insulin delivery system that provides ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

Mumbai: Cipla Limited has announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the ...

Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution ...

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India.      Afrezza, ...